12.4 HRCT, Lung Nodules & Low-Dose Lung Cancer Screening
Key Takeaways
- ARRT's 'lungs' leaf item explicitly names HRCT, interstitial lung disease (ILD), and nodule evaluation together, while low-dose lung cancer screening is its own separate leaf item with a distinct patient population and dose target.
- High-resolution CT (HRCT) uses thin (about 1-1.25 mm) slices with a sharp reconstruction kernel, and adds prone imaging to distinguish true fibrosis from dependent atelectasis, plus inspiratory/expiratory pairs to reveal air trapping in small-airways disease.
- The Fleischner Society's 2017 guidelines base incidental solid pulmonary nodule follow-up on size and patient risk: nodules under 6 mm generally need no routine follow-up, 6-8 mm nodules get a 6-12 month follow-up CT, and larger nodules warrant closer-interval or same-visit workup.
- Low-dose CT (LDCT) lung cancer screening under current USPSTF criteria targets adults 50-80 years old with at least a 20 pack-year smoking history who currently smoke or quit within the past 15 years, using a noncontrast, reduced-dose annual scan.
- Lung-RADS is the ACR's standardized reporting and management system for screening-detected nodules (categories 0 through 4), and it is a distinct system from the Fleischner guidelines, which apply to incidentally found nodules on non-screening scans.
Why This Topic Is Tested
ARRT's outline lists "lungs (e.g., HRCT, ILD, nodule)" as one leaf item and "low-dose lung screening" as a second, separate leaf item. That separation is intentional: general lung parenchymal imaging (technique-focused, covering interstitial disease and incidental nodules) and lung cancer screening (population-focused, covering a specific at-risk patient group and a standardized reporting system) test different skills. Both are high real-world relevance topics — interstitial lung disease workups and annual screening programs are common daily CT volume — and the exam expects protocol-selection and follow-up-interval reasoning rather than diagnostic image interpretation.
High-Resolution CT (HRCT) Technique
HRCT is a dedicated protocol for evaluating the lung interstitium, most often for suspected interstitial lung disease (ILD). It differs from a routine chest CT in three specific ways: thin sections (roughly 1-1.25 mm, versus 3-5 mm on a standard chest CT), a sharp/high-spatial-frequency reconstruction kernel that sacrifices some noise performance in exchange for finer parenchymal detail, and frequently prone positioning for at least part of the acquisition. Prone imaging is the single detail most often tested here: it distinguishes dependent atelectasis (a normal, gravity-related density at the posterior lung bases that resolves prone) from true early fibrosis (a fixed abnormality that persists regardless of position) — a distinction a supine-only scan cannot reliably make. Some HRCT protocols add paired inspiratory and end-expiratory acquisitions to detect air trapping, seen as regions of abnormally low attenuation ('mosaic attenuation') that fail to increase in density on the expiratory series, a finding associated with small-airways diseases such as constrictive bronchiolitis or hypersensitivity pneumonitis.
A related but separate technique point tested elsewhere on the exam (and worth recalling here): a routine contrast-enhanced chest CT's raw data is commonly reconstructed twice from the same acquisition — once with a smooth/soft-tissue kernel for the mediastinum and once with a sharp/lung kernel for the parenchyma — because a single kernel cannot simultaneously optimize both soft-tissue contrast and fine lung detail.
Fleischner Society Nodule Follow-Up
The Fleischner Society's 2017 guidelines standardize follow-up for incidentally discovered pulmonary nodules (found on a scan performed for an unrelated reason, not a screening exam). For a solid, single nodule, follow-up is driven primarily by size:
| Nodule size | Typical follow-up |
|---|---|
| Less than 6 mm | No routine follow-up needed for most patients (optional CT at 12 months if high risk) |
| 6-8 mm | Follow-up CT at 6-12 months, then consider a further check at 18-24 months |
| Greater than 8 mm | Consider CT at 3 months, PET/CT, or tissue sampling depending on the clinical picture |
Subsolid (ground-glass or part-solid) nodules are managed on a longer timeline than solid nodules of the same size, because the adenocarcinoma spectrum they can represent tends to grow slowly — a persistent part-solid nodule may warrant annual follow-up for five years or more rather than the shorter intervals used for solid nodules. The exam-testable principle is simpler than the full granular table: bigger nodule, or any solid component growth, means a shorter follow-up interval or more aggressive workup, and subsolid nodules are followed longer, not shorter, than their size alone would suggest for a solid lesion.
Low-Dose Lung Cancer Screening (LDCT)
Low-dose CT lung cancer screening targets a specific high-risk population, current USPSTF criteria: adults ages 50 to 80, with at least a 20 pack-year smoking history, who are current smokers or quit within the past 15 years. Screening is performed annually and stops once a patient has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability to tolerate curative lung surgery. Technically, LDCT is a noncontrast, reduced-dose acquisition (typically well under half the mAs of a standard diagnostic chest CT, delivering an effective dose around 1-1.5 mSv versus roughly 7 mSv for a full diagnostic chest CT) at standard kVp, reconstructed with thin slices for accurate nodule measurement. This is a materially different exam from a standard diagnostic chest CT ordered to characterize an already-known abnormality, which uses full-dose technique and often IV contrast — a frequent exam trap conflates the two, describing a diagnostic-dose contrast study and calling it a "screening" exam.
Lung-RADS
Findings on a screening LDCT are reported using the ACR's Lung-RADS system, a category scheme distinct from the Fleischner guidelines:
- Category 0 — incomplete; additional prior imaging needed for comparison
- Category 1 — negative; no nodules, or nodules that are clearly benign
- Category 2 — benign appearance or behavior (e.g., fully calcified or fat-containing nodules, or lesions stable over time); continue annual screening
- Category 3 — probably benign; low likelihood of cancer, with a short-interval (about 6-month) follow-up CT recommended
- Category 4 (4A/4B/4X) — suspicious; findings warrant closer-interval CT, PET/CT, or tissue sampling depending on subcategory
The key distinction to keep straight for the exam: Fleischner guidelines manage incidental nodules found on non-screening scans, while Lung-RADS manages nodules found on a dedicated LDCT screening exam — the two systems apply to different clinical contexts even though both ultimately recommend a follow-up interval based on nodule characteristics.
Exam Scenario
A 63-year-old with a 35 pack-year smoking history who quit 8 years ago undergoes annual LDCT screening, which detects a new 5 mm solid nodule with no suspicious features. Under Lung-RADS, this is most consistent with Category 2 (benign appearance/behavior for a small, stable nodule), and the patient continues routine annual screening rather than an early short-interval follow-up — a very small, non-suspicious nodule on a screening exam does not by itself trigger Category 3 or 4 management.
An HRCT is performed to evaluate suspected interstitial lung disease. Why is prone imaging typically added to the protocol?
Which patient meets current USPSTF criteria for annual low-dose CT lung cancer screening?
A solid pulmonary nodule measuring 7 mm is found incidentally on a CT performed for an unrelated indication. According to Fleischner Society guidelines, what is the most appropriate initial management?